Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

PURPOSE: AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to assess their ability to prevent recurrence in HER2 expressing breast cancer patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Tommy A., Mittendorf, Elizabeth A., Hale, Diane F., Myers, John W., Peace, Kaitlin M., Jackson, Doreen O., Greene, Julia M., Vreeland, Timothy J., Clifton, G. Travis, Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Symanowski, J., Murray, James L., Ponniah, Sathibalan, Anastasopoulou, E. A., Pistamaltzian, N. F., Baxevanis, Constantin N., Perez, Sonia A., Papamichail, Michael, Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188712/
https://www.ncbi.nlm.nih.gov/pubmed/32323103
http://dx.doi.org/10.1007/s10549-020-05638-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188712/
https://www.ncbi.nlm.nih.gov/pubmed/32323103
http://dx.doi.org/10.1007/s10549-020-05638-x

Ejemplares similares